Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Some real Redux data

Some real Redux data

Data published in the New England Journal of Medicine provide evidence from controlled clinical trials that Interneuron Pharmaceuticals Inc.'s Redux dexfenfluramine and other diet drugs may cause heart valve abnormalities, as anecdotal evidence had suggested.

Two of the studies looked at echocardiographic data from patients who

Read the full 491 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers